LUNGevity Foundation welcomes FDA approval of Zykadia for advanced stages of lung can

[News]

LUNGevity Foundation applauds the FDA approval of Zykadia™ for the subset of anaplastic lymphoma kinase-positive (ALK+) patients with advanced cases of non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

More... (http://www.news-medical.net/news/20140502/LUNGevity-Foundation-welcomes-FDA-approval-of-Zykadia-for-advanced-stages-of-lung-cancer.aspx)